Alzamend Neuro announced receipt of a “Study May Proceed” letter from the FDA for the initiation of study AL001-PTSD01, a Phase IIA clinical study of AL001 for treatment of patients with PTSD.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALZN:
- Alzamend Neuro gets ‘Study May Proceed’ letter for AL001 from FDA to treat MLS
- Alzamend Neuro regains compliance with Nasdaq
- Alzamend Neuro submits AL001-PTSD01 IND application to FDA
- Alzamend Neuro annouces one-for-fifteen reverse stock split
- Alzamend Neuro submits AL001-MDD01 IN application to FDA
